arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive Leaguearthyper-972Research ArticleОБЗОРЫREVIEWSСходство патогенеза артериальной гипертензии и ишемической болезни сердца - одно из условий единого подхода к терапииМаколкинВ. И.noemail@neicon.ruМосковская медицинская академия им. И.М. СеченоваRussian Federation2005280420051129093Copyright © Маколкин В.И., 20052005Маколкин В.И.Маколкин В.И.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/972ReferencesМясников АЛ. Гипертоническая болезнь и атеросклероз. М: Медицина. 1965.Мясников АЛ. Гипертоническая болезнь и атеросклероз. М: Медицина. 1965.MacMahon S., Peto R., Culter J. et at. Blood pressure, stroke and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990:335 (8692): 765-74.MacMahon S., Peto R., Culter J. et at. Blood pressure, stroke and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990:335 (8692): 765-74.Staessen J.A., Fagard R., Thijs L. et al. Systolic Hypertension in Europe (90-Eur) Trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997: 350: 757-64.Staessen J.A., Fagard R., Thijs L. et al. Systolic Hypertension in Europe (90-Eur) Trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997: 350: 757-64.Drau V. Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991: 121 (4 Pt): 1244-63.Drau V. Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991: 121 (4 Pt): 1244-63.Resink T.J., Hahn A.W., Scott-Burden T. et al. Include endotelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Bioch. Biophys. Commun 1990; 168 (3); 1303-10.Resink T.J., Hahn A.W., Scott-Burden T. et al. Include endotelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Bioch. Biophys. Commun 1990; 168 (3); 1303-10.Gomma A., Henderson J., Purcell H., Fox K. The clinical application of ACE inhibitors in coronary artery disease, Brit J Card. 2002: 9: 158-62.Gomma A., Henderson J., Purcell H., Fox K. The clinical application of ACE inhibitors in coronary artery disease, Brit J Card. 2002: 9: 158-62.Cooper M.S. Am J Card 1990.Cooper M.S. Am J Card 1990.Eichstaedt H.W., Meterns D.S., Dame H. Perfusion. 1994: 7: 426-9.Eichstaedt H.W., Meterns D.S., Dame H. Perfusion. 1994: 7: 426-9.Rizzoni D.J. Hypertension. 1997.Rizzoni D.J. Hypertension. 1997.Lariades C., Mayor G., Dies J. Am J Card 1994: 7 (1): 52-8.Lariades C., Mayor G., Dies J. Am J Card 1994: 7 (1): 52-8.Brilla C.G., Funk R.C., Rupp H. Circulation, 2000: 102 (12): 1388-93.Brilla C.G., Funk R.C., Rupp H. Circulation, 2000: 102 (12): 1388-93.Cleland J.G., Erhardt L., Murray G. et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report the AIRE study investigators. Fur Heart 1997; 19: 41-51.Cleland J.G., Erhardt L., Murray G. et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report the AIRE study investigators. Fur Heart 1997; 19: 41-51.Pfeffer M.A., Braunwald E., Miye L.A. et al. Effect of captapril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992: 327: 669-77.Pfeffer M.A., Braunwald E., Miye L.A. et al. Effect of captapril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992: 327: 669-77.Torp-Pedersen C., Roher L., Carisen J. Angiotensin-converting enzyme inhibitor after myocardial infarction: the Trandolapril cardiac Evaluation study. Am Heart J 1996; 132: 235-43.Torp-Pedersen C., Roher L., Carisen J. Angiotensin-converting enzyme inhibitor after myocardial infarction: the Trandolapril cardiac Evaluation study. Am Heart J 1996; 132: 235-43.GISSI-3 study group. Six-month effect of early treatment with lisinopril and transdermal glyceryl trinitrate singly and withdrawn six weeks after acute myocardial infarction. J Am Coll Card 1996; 27: 337-44.GISSI-3 study group. Six-month effect of early treatment with lisinopril and transdermal glyceryl trinitrate singly and withdrawn six weeks after acute myocardial infarction. J Am Coll Card 1996; 27: 337-44.Ambrosini E., Borghi C., Magnani D. The effect of zofenopril on morbidity and mortality after anterior myocardial infarction. N Engl J Med 1995: 332: 80-5.Ambrosini E., Borghi C., Magnani D. The effect of zofenopril on morbidity and mortality after anterior myocardial infarction. N Engl J Med 1995: 332: 80-5.The HOPE study investigators. Effect of an angiotensin-converting-enzyme, ramipril, on cardiovascular events in high risk patients. N Engl Med J 2000: 342: 145-53.The HOPE study investigators. Effect of an angiotensin-converting-enzyme, ramipril, on cardiovascular events in high risk patients. N Engl Med J 2000: 342: 145-53.Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA study). The Lancet. Published online September 1, 2003: 1-7.Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA study). The Lancet. Published online September 1, 2003: 1-7.Pfeffer M.A., Domanski M., Rosenberg Y. et al. Prevention of events with angiotensin-converting enzyme inhibition (the РEACE study design). Am J Card 1998: 82: 25H-30H.Pfeffer M.A., Domanski M., Rosenberg Y. et al. Prevention of events with angiotensin-converting enzyme inhibition (the РEACE study design). Am J Card 1998: 82: 25H-30H.Hansson L., Zanchetti A., Caruthers S.G. et al. Effect of intensive blood pressure lowering and tow dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998: 351: 1755-62.Hansson L., Zanchetti A., Caruthers S.G. et al. Effect of intensive blood pressure lowering and tow dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998: 351: 1755-62.Hannson L., Lidholm L.H., Ekhom T. el al. Randomised trial of old and new antihypertensive drugs in the elderly patients (STOP-hypertension-2). Lancet 1999: 354: 1751-6.Hannson L., Lidholm L.H., Ekhom T. el al. Randomised trial of old and new antihypertensive drugs in the elderly patients (STOP-hypertension-2). Lancet 1999: 354: 1751-6.Hannson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effect of calcium antagonists compared with diuretics and fi-blockers on cardiovascular mjrhiditi and mjrtaliti in hypertension (NORDIL study). Lancet 2000: 356: 359-65.Hannson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effect of calcium antagonists compared with diuretics and fi-blockers on cardiovascular mjrhiditi and mjrtaliti in hypertension (NORDIL study). Lancet 2000: 356: 359-65.Zanchetti A., Agahiti Rosei E., Dal Palu С. et al. The verapamil in hypertension and atherosclerosis study (VHAS). J Hypertension 1998; 16: 1667-76.Zanchetti A., Agahiti Rosei E., Dal Palu С. et al. The verapamil in hypertension and atherosclerosis study (VHAS). J Hypertension 1998; 16: 1667-76.Brown M.J., Palmer C.R., Castaigne A. et al. Morbiditi and mortaliti in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in International Nifedipine GITS study (INSIGHT), Lancet 2000: 356: 366-72.Brown M.J., Palmer C.R., Castaigne A. et al. Morbiditi and mortaliti in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in International Nifedipine GITS study (INSIGHT), Lancet 2000: 356: 366-72.Gelis H., Yodfat V., Thijs L. et at. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract 1996; 13: 138-43.Gelis H., Yodfat V., Thijs L. et at. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. Fam Pract 1996; 13: 138-43.Watts R.W. et al. A placebo-controlled comparison of diltiazem and amlodipine mjnjtherapy in essential hypertension using 24-h ambulatory monitoring. Blood Press. 1998: 7 (l): 25-30.Watts R.W. et al. A placebo-controlled comparison of diltiazem and amlodipine mjnjtherapy in essential hypertension using 24-h ambulatory monitoring. Blood Press. 1998: 7 (l): 25-30.Kloner R.A., Sowers J.R., DiBona G.F. el al. Sex- and age-related antihypertensive effect of amlodipine. Am J Card 1996; 77: 13-22.Kloner R.A., Sowers J.R., DiBona G.F. el al. Sex- and age-related antihypertensive effect of amlodipine. Am J Card 1996; 77: 13-22.Motor Outcomes in High-Risk Hypertensive Patients Randomised to Angiotensin-Converting Ensyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMMA December 18, 2002: (288) 23: 2981-98.Motor Outcomes in High-Risk Hypertensive Patients Randomised to Angiotensin-Converting Ensyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMMA December 18, 2002: (288) 23: 2981-98.Белоусов Ю.Б., Грацианская А.Н. Клиническая фармакология амлодипина. Изд. «Универсум Паблишинг». 1998.Белоусов Ю.Б., Грацианская А.Н. Клиническая фармакология амлодипина. Изд. «Универсум Паблишинг». 1998.Фельдшерова Н.А., Семернин Е.Н. Амлодипин: обзор клинических исследований. Качественная клин. практика. 2002; 2: 27-33.Фельдшерова Н.А., Семернин Е.Н. Амлодипин: обзор клинических исследований. Качественная клин. практика. 2002; 2: 27-33.Liehson P.R., Crandits G.A., Dianzumba S. et al. Comparison Of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (ТОМHS). Circulation 1995: 91: 698-706.Liehson P.R., Crandits G.A., Dianzumba S. et al. Comparison Of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (ТОМHS). Circulation 1995: 91: 698-706.Derty J.M. Amlodipine and the total ischemic burden: Circadian Anti-Ischemia Program in Europe (CAPE) trial - Methodology, safely and toleration. Cardiology 1994: 85 (Suppl. 2): 24-30.Derty J.M. Amlodipine and the total ischemic burden: Circadian Anti-Ischemia Program in Europe (CAPE) trial - Methodology, safely and toleration. Cardiology 1994: 85 (Suppl. 2): 24-30.Montro M., Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37: 1410-3.Montro M., Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37: 1410-3.Reichardt B. Antiatherosclerolic effect of lacidipine. Pharmocotherap 1995: 6: 37-43.Reichardt B. Antiatherosclerolic effect of lacidipine. Pharmocotherap 1995: 6: 37-43.Pitt B., Byington R.P., Furberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.Pitt B., Byington R.P., Furberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.Luhsen J., Poole-Wilson P.A., Pocock Sj. et al. Design and current of ACTION A coronary disease Trial investigating Outcome with Nifedipine CITS. Eur Heart J 1998; 19 (Suppl. 1): 120-32.Luhsen J., Poole-Wilson P.A., Pocock Sj. et al. Design and current of ACTION A coronary disease Trial investigating Outcome with Nifedipine CITS. Eur Heart J 1998; 19 (Suppl. 1): 120-32.
The authors declare that there are no conflicts of interest present.